IDRx

🗓 Founded 2022👥 20 employees💰 Last funded Apr 2022
Biotechnology Research🌐 idrx.com
Website LinkedIn
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines with highly -selective, purposely -designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease. Founded in 2022, IDRx’s leadership team has extensive experience in drug development, and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in IDRx?
IDRx has 1 investors on record on gritt.io, including 1 early-stage backers.
When did IDRx last raise funding?
The most recent investment in IDRx recorded on gritt.io was in April 2022.
When was IDRx founded?
IDRx was founded in 2022.
What industry is IDRx in?
IDRx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.